Triumph Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.64M Buy
3,038
+673
+28% +$688K 0.66% 34
2026
Q1
$2.18M Buy
2,365
+848
+56% +$860K 0.44% 50
2025
Q4
$1.63M Sell
1,517
-2,796
-65% -$2.67M 0.35% 59
2025
Q3
$3.29M Buy
4,313
+1,286
+42% +$957K 0.88% 29
2025
Q2
$2.36M Buy
3,027
+1,850
+157% +$1.44M 0.71% 27
2025
Q1
$972K Sell
1,177
-199
-14% -$166K 0.32% 74
2024
Q4
$1.06M Buy
1,376
+180
+15% +$149K 0.36% 57
2024
Q3
$1.06M Buy
1,196
+531
+80% +$477K 0.38% 55
2024
Q2
$602K Sell
665
-101
-13% -$80.8K 0.24% 101
2024
Q1
$582K Sell
766
-1,474
-66% -$1.05M 0.24% 102
2023
Q4
$1.31M Buy
2,240
+1,392
+164% +$813K 0.55% 41
2023
Q3
$455K Buy
848
+10
+1% +$5.15K 0.21% 110
2023
Q2
$393K Sell
838
-367
-30% -$154K 0.18% 116
2023
Q1
$414K Buy
1,205
+329
+38% +$111K 0.21% 96
2022
Q4
$320K Buy
+876
New +$311K 0.17% 132
2022
Q2
Sell
-2,015
Closed -$577K 222
2022
Q1
$577K Sell
2,015
-504
-20% -$130K 0.25% 102
2021
Q4
$696K Sell
2,519
-1,111
-31% -$282K 0.3% 80
2021
Q3
$839K Buy
+3,630
New +$896K 0.39% 62

Other funds holding LLY

Triumph Capital Management's LLY Position: Q2 2026 in Review

Triumph Capital Management increased its Eli Lilly (LLY) stake by 28% in Q2 2026, buying an estimated $688K and bringing the position to 3,038 shares worth $3.64M. The position accounts for 0.66% of the portfolio, ranked #34.

Triumph Capital Management first reported a position in LLY in Q3 2021 and has held it in 18 quarters since. 1,063 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Triumph Capital Management held 3,038 shares of Eli Lilly worth $3.64M as of Q2 2026.
  • Triumph Capital Management bought 673 Eli Lilly shares in Q2 2026, an estimated $688K.
  • Eli Lilly made up 0.66% of Triumph Capital Management's portfolio in Q2 2026, its #34 holding.
  • Triumph Capital Management first reported a position in Eli Lilly in Q3 2021 and has held it in 18 quarters since.
  • 1,063 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.